Intervention

Denosumab

ClinicalTrials.gov intervention label

Clinical trials30
Recruiting3
Common conditions25
Lead sponsors shown15

Clinical trials

30 shown
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisNCT06374459 · 2025-01-30
RECRUITING
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingNCT06749886 · 2024-11-19
RECRUITING
Denosumab for Type 1 DiabetesNCT06524960 · 2024-09-03
RECRUITING
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationNCT04711109 · 2023-02-14
ACTIVE_NOT_RECRUITING
RANKL Inhibition and Mammographic Breast DensityNCT04067726 · 2019-08-27
ACTIVE_NOT_RECRUITING
RANKL Inhibition and Breast Tissue BiomarkersNCT03629717 · 2018-06-01
COMPLETED
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsNCT03070002 · 2017-10-19
TERMINATED
Effect of Denosumab in Erosion Healing in RANCT03239080 · 2017-06-19
COMPLETED
Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · 2017-02-13
COMPLETED
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone MetastasesNCT02721433 · 2016-08-01
COMPLETED
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasesNCT02758132 · 2016-03-01
TERMINATED
Denosumab and MRI Breast ImagingNCT02613416 · 2015-11-01
COMPLETED
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerNCT02366130 · 2015-02-11
COMPLETED
Denosumab for Breast Cancer With Bone MetsNCT01952054 · 2015-02-09
TERMINATED
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapyNCT02129699 · 2015-01-06
TERMINATED
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung CancerNCT01951586 · 2013-12-31
COMPLETED
A Study to Evaluate Denosumab in Young Patients With Primary Breast CancerNCT01864798 · 2013-07-01
TERMINATED
RA Denosumab on Bone Microstructure StudyNCT01770106 · 2012-12-01
COMPLETED
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast CancerNCT01545648 · 2012-11-01
TERMINATED
Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerNCT01419717 · 2011-11-22
COMPLETED
Effects of Denosumab on the Pharmacokinetics of EtanerceptNCT01294397 · 2011-03-01
TERMINATED
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate CancerNCT01824342 · 2011-01-01
COMPLETED
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)NCT01077154 · 2010-06-02
TERMINATED
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone LossNCT00925600 · 2009-11-30
COMPLETED
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate CancerNCT00838201 · 2009-02-01
COMPLETED
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyNCT00556374 · 2006-12-18
COMPLETED
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.NCT00330759 · 2006-06-01
COMPLETED
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.NCT00321464 · 2006-04-01
COMPLETED
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerNCT00286091 · 2006-01-24
COMPLETED
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerNCT00091832 · 2004-09-01
COMPLETED

Common conditions

Breast Cancer8Prostate Cancer4Rheumatoid Arthritis3Bone Metastases2Bone Metastases in Subjects With Advanced Breast Cancer2Breast Neoplasms2Cancer2Castrate-resistant Prostate Cancer2Osteopenia2Osteoporosis2Bone Metastases in Men With Hormone-Refractory Prostate Cancer1BRCA1 Mutation1Breast Cancer Female NOS1Breast Cancer Prevention1Breast Carcinoma1Breast Carcinoma Metastatic in the Bone1Breast Diseases1Carcinoma1Cataract1Circulating Tumor Cell Count1Dense Breasts1Early Stage Breast Cancer1Estrogen Receptor Positive1HER2 Positive Breast Cancer1HER2/Neu Negative1

Trial status mix

COMPLETED17
TERMINATED8
RECRUITING3
ACTIVE_NOT_RECRUITING2

Phase mix

PHASE215
PHASE311
PHASE13
PHASE42
EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.